Carmelina Di Pasquale1, Erica Gentilin1, Simona Falletta1, Mariaenrica Bellio1, Mattia Buratto1, Ettore Degli Uberti1,2, Maria Chiara Zatelli3,4. 1. Department of Medical Sciences, Section of Endocrinology & Internal Medicine, University of Ferrara, Ferrara, Italy. 2. Laboratorio in rete del Tecnopolo "Tecnologie delle terapie avanzate" (LTTA) of the University of Ferrara, Ferrara, Italy. 3. Department of Medical Sciences, Section of Endocrinology & Internal Medicine, University of Ferrara, Ferrara, Italy. ztlmch@unife.it. 4. Laboratorio in rete del Tecnopolo "Tecnologie delle terapie avanzate" (LTTA) of the University of Ferrara, Ferrara, Italy. ztlmch@unife.it.
Abstract
PURPOSE: Insulin-like growth factor 1 (IGF1) controls growth hormone (GH) secretion via a negative feed-back loop that may disclose novel mechanisms possibly useful to control GH hyper-secretion. Our aim was to understand whether PI3K/Akt/mTOR pathway is involved in IGF1 negative feedback on GH secretion. METHODS: Cell viability, GH secretion, Akt, and Erk 1/2 phosphorylation levels in the rat GH3 cell line were assessed under treatment with IGF1 and/or everolimus, an mTOR inhitior. RESULTS: We found that IGF1 improves rat GH3 somatotroph cell viability via the PI3K/Akt/mTOR pathway and confirmed that IGF1 exerts a negative feedback on GH secretion by a transcriptional mechanism. We demonstrated that the negative IGF1 loop on GH secretion requires Akt activation that seems to play a pivotal role in the control of GH secretion. Furthermore, Akt activation is independent of PI3K and probably mediated by mTORC2. In addition, we found that Erk 1/2 is not involved in GH3 cell viability regulation, but may have a role in controlling GH secretion, independently of IGF1. CONCLUSION: Our data confirm that mTOR inhibitors may be useful to reduce pituitary adenoma cell viability, while Erk 1/2 pathway may be considered as a useful therapeutic target to control GH secretion. Our results open the field for further studies searching for effective drugs to control GH hyper-secretion.
PURPOSE:Insulin-like growth factor 1 (IGF1) controls growth hormone (GH) secretion via a negative feed-back loop that may disclose novel mechanisms possibly useful to control GH hyper-secretion. Our aim was to understand whether PI3K/Akt/mTOR pathway is involved in IGF1 negative feedback on GH secretion. METHODS: Cell viability, GH secretion, Akt, and Erk 1/2 phosphorylation levels in the rat GH3 cell line were assessed under treatment with IGF1 and/or everolimus, an mTOR inhitior. RESULTS: We found that IGF1 improves rat GH3 somatotroph cell viability via the PI3K/Akt/mTOR pathway and confirmed that IGF1 exerts a negative feedback on GH secretion by a transcriptional mechanism. We demonstrated that the negative IGF1 loop on GH secretion requires Akt activation that seems to play a pivotal role in the control of GH secretion. Furthermore, Akt activation is independent of PI3K and probably mediated by mTORC2. In addition, we found that Erk 1/2 is not involved in GH3 cell viability regulation, but may have a role in controlling GH secretion, independently of IGF1. CONCLUSION: Our data confirm that mTOR inhibitors may be useful to reduce pituitary adenoma cell viability, while Erk 1/2 pathway may be considered as a useful therapeutic target to control GH secretion. Our results open the field for further studies searching for effective drugs to control GH hyper-secretion.
Authors: M Musat; M Korbonits; B Kola; N Borboli; M R Hanson; A M Nanzer; J Grigson; S Jordan; D G Morris; M Gueorguiev; M Coculescu; S Basu; A B Grossman Journal: Endocr Relat Cancer Date: 2005-06 Impact factor: 5.678
Authors: Maria Chiara Zatelli; Daniela Piccin; Cristina Vignali; Federico Tagliati; Maria Rosaria Ambrosio; Marta Bondanelli; Vincenzo Cimino; Antonio Bianchi; Herbert A Schmid; Massimo Scanarini; Alfredo Pontecorvi; Laura De Marinis; Giulio Maira; Ettore C degli Uberti Journal: Endocr Relat Cancer Date: 2007-03 Impact factor: 5.678
Authors: Erica Gentilin; Carmelina Di Pasquale; Martina Rossi; Federico Tagliati; Teresa Gagliano; Roberta Rossi; Mariarosa Pelizzo; Isabella Merante Boschin; Ettore C Degli Uberti; Maria Chiara Zatelli Journal: Front Endocrinol (Lausanne) Date: 2015-05-05 Impact factor: 5.555
Authors: Claudia Pivonello; Roberta Patalano; Domenico Solari; Renata S Auriemma; Federico Frio; Francesca Vitulli; Ludovica F S Grasso; Marialuisa Di Cera; Maria Cristina De Martino; Luigi M Cavallo; Paolo Cappabianca; Annamaria Colao; Rosario Pivonello Journal: Endocrine Date: 2018-07-31 Impact factor: 3.633
Authors: Tomasz M Grzywa; Klaudia Klicka; Beata Rak; Dawid Mehlich; Filip Garbicz; Grzegorz Zieliński; Maria Maksymowicz; Emir Sajjad; Paweł K Włodarski Journal: Endocrine Date: 2019-06-04 Impact factor: 3.633